or Try an Advanced Search...

    Morpholines Stocks List

    Symbol Grade Name % Change
    INCY C Incyte Corporation -0.93
    KRON D Kronos Bio, Inc. 1.66
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Biology Cancer Therapeutics Chemical Compounds Clinical Trial Product Clinical Trial Products Cyclin Dependent Kinase Diabetic Nephropathy Entospletinib Enzymes Hematologic Malignancies Inflammation Janus Kinase Inhibitor Myelofibrosis Nasdaq 100 Nitriles Novel Cancer Organic Compounds

    Related ETFs - A few ETFs which own one or more of the above listed Morpholines stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 5.36
    CANC D Tema Oncology ETF 4.1
    FBT D First Trust Amex Biotech Index Fund 3.97
    PBE D PowerShares Dynamic Biotech & Genome 3.35
    XBI D SPDR S&P Biotech ETF 3.29
    View all Morpholines ETFs...
    Compare ETFs
    Compare CANC to FBT Compare FBT to XBI Compare IDNA to XBI

        Morpholines Stocks Recent News

        Date Stock Title
        Nov 21 INCY Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
        Nov 19 INCY Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
        Nov 19 INCY Equity Markets Close Mixed Ahead of Nvidia Earnings
        Nov 19 INCY S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
        Nov 19 INCY Sector Update: Health Care Stocks Decline
        Nov 19 INCY Top Midday Decliners
        Nov 19 INCY Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
        Nov 19 INCY Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
        Nov 19 INCY Incyte seesaws on report of potential Merck takeover interest
        Nov 19 INCY Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
        Nov 19 INCY Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.
        Nov 19 INCY Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
        Nov 19 INCY Incyte Faces Challenges but Remains Focused on Strategic Growth
        Nov 19 INCY Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
        Nov 19 INCY Incyte sinks on setback for drugs acquired in $750M buyout
        Nov 18 INCY Incyte drops 9% after pausing enrollment in study for urticaria asset
        Nov 18 INCY Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
        Nov 18 INCY Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?
        Nov 17 KRON Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 16 INCY Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Biology Cancer Therapeutics Chemical Compounds Clinical Trial Product Clinical Trial Products Cyclin Dependent Kinase Diabetic Nephropathy Entospletinib Enzymes Hematologic Malignancies Inflammation Janus Kinase Inhibitor Myelofibrosis Nasdaq 100 Nitriles Novel Cancer Organic Compounds
        Morpholines

        Morpholine is an organic chemical compound having the chemical formula O(CH2CH2)2NH. This heterocycle features both amine and ether functional groups. Because of the amine, morpholine is a base; its conjugate acid is called morpholinium. For example, treating morpholine with hydrochloric acid makes the salt morpholinium chloride.
        The naming of morpholine is attributed to Ludwig Knorr, who incorrectly believed it to be part of the structure of morphine.

        More about Morpholines
        Browse All Tags